Sarepta Therapeutics addressed reports of two patient deaths listed on the FDA Adverse Event Reporting System associated with Elevidys, its gene therapy for Duchenne muscular dystrophy. The company stated that investigations attribute neither death to the treatment, underscoring no impact on current therapy shipments for ambulatory patients. This follows previous fatalities linked to acute liver failure with Elevidys earlier this year, highlighting ongoing safety scrutiny for novel gene therapies.